Drug product attributes predict clinical efficacy in betibeglogene autotemcel gene therapy for β-thalassemia von Whitney, Dustin, Shestopalov, Ilya, Fincker, Maeva, d’Anjou, Marc, Kral, Kelly, Gayron, Marisa, Pierciey, Francis J., Colvin, Richard A.

Volltext

Results from the Completed Hgb-205 Trial of Lentiglobin for β-Thalassemia and Lentiglobin for Sickle Cell Disease Gene Therapy von Magrin, Elisa, Semeraro, Michaela, Magnani, Alessandra, Puy, Hervé, Miccio, Annarita, Hebert, Nicolas, Diana, Jean-Sebastien, Lefrere, Francois, Suarez, Felipe, Hermine, Olivier, Brousse, Valentine, Poirot, Catherine, Bourget, Philippe, El Nemer, Wassim, Guichard, Isabelle, Moshous, Despina, Neven, Benedicte, Monpoux, Fabrice, Poirée, Marilyne, Bartolucci, Pablo, Meritet, Jean-François, Grévent, David, Lefebvre, Thibaud, Asmal, Mohammed, Whitney, Erin, Gayron, Marisa, Huang, Wenmei, Funck-Brentano, Isabelle, de Montalembert, Mariane, Joseph, Laure, Ribeil, Jean-Antoine, Cavazzana, Marina

Volltext

Results from the Hgb-207 (Northstar-2) Trial: A Phase 3 Study to Evaluate Safety and Efficacy of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) in Patients... von Walters, Mark C., Hongeng, Suradej, Kwiatkowski, Janet L., Locatelli, Franco, Porter, John B., Sauer, Martin G., Thrasher, Adrian J, Thuret, Isabelle, Yannaki, Evangelia, Elliot, Heidi, Gayron, Marisa, Asmal, Mohammed, Thompson, Alexis A

Volltext